Notícias e Atividades da Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals é uma das ...

• Russell 3000;
• TOB Iconic 10,000.

Arrowhead Pharmaceuticals é uma empresa listada sob o símbolo ARWR (US).

Fusão, aquisição e financiamento envolvendo Arrowhead Pharmaceuticals.

• Arrowhead Pharmaceuticals acaba de anunciar uma arrecadação de fundos de 825 milhões de dólares. (publicado em 27 de novembro de 2024).

Veja o organograma con seus 27 executivos principais

Biografias mais buscadas da Arrowhead Pharmaceuticals

• Christopher Anzalone, Chief Executive Officer and Chairman of the ...
• Hongbo Lu, Director
• Mauro Ferrari, Director

Recentes movimentos de executivos em Arrowhead Pharmaceuticals

• Kenneth Myszkowski, Chief Financial Officer, deixou a Companhia  (Notícia publicada em 16 de abril de 2025).
• Daniel Apel, ingressou na Companhia como Chief Financial Officer  (Notícia publicada em 16 de abril de 2025).
• Matt Pulisic, Vice President of Finance, deixou a Companhia  (Notícia publicada em 13 de fevereiro de 2025).

Clique aqui para ver outras movimentos em Arrowhead Pharmaceuticals

Criar um alerta
para seguir os movimentos de executivos da Arrowhead Pharmaceuticals.

Arrowhead Pharmaceuticals possui 2.350 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e Johnson & Johnson Innovative Medicine DIA (Estados Unidos).

Popular M&A news in Biotecnologia

• Transcarent and Accolade have merged  (publicado em 9 de abril de 2025)..
• Kashiv BioSciences acaba de anunciar uma arrecadação de fundos de 150 milhões de dólares. (publicado em 7 de abril de 2025).
• Atsena Therapeutics acaba de anunciar uma arrecadação de fundos de 150 milhões de dólares. (publicado em 4 de abril de 2025).

Outros contatos sugeridos na indústria do Biotecnologia

• Kristina Burow - Director da Scholar Rock
• Steven Gillis - Chairman of the Board da VBI Vaccines
• Ali Behbahani - Non-Executive Director da Adaptimmune Therapeutics

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Arrowhead Pharmaceuticals

• Arrowhead Pharmaceuticals to Participate in Upcoming December 2024 Conferences - Arrowhead Pharmaceuticals, Inc.
• Arrowhead Pharmaceuticals Reports 2024 Fiscal Year-End Results - Arrowhead Pharmaceuticals, Inc.
• Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity - Arrowhead Pharmaceuticals, Inc.
• Arrowhead Pharmaceuticals Announces Global License and Collaboration Agreement with Sarepta Therapeutics for Multiple Clinical and Preclinical Programs - Arrowhead Pharmaceuticals, Inc.
• Arrowhead Pharmaceuticals Presents New Data at AHA24 from PALISADE Phase 3 Study and Open-Label Extension from MUIR and SHASTA-2 Studies of Plozasiran - Arrowhead Pharmaceuticals, Inc.
• Arrowhead Pharmaceuticals Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome - Arrowhead Pharmaceuticals, Inc.
• Arrowhead Pharmaceuticals to Webcast 2024 Fiscal Year End Results - Arrowhead Pharmaceuticals, Inc.
• Arrowhead Pharmaceuticals to Participate in Upcoming November 2024 Conferences - Arrowhead Pharmaceuticals, Inc.
• Arrowhead Pharmaceuticals Launches New Disease Awareness Campaign, ‘We’ll Get There Soon,’ to Inspire Hope for the Rare Disease Community Affected by Familial Chylomicronemia Syndrome - Arrowhead Pharmaceuticals, Inc.
• Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Arrowhead Pharmaceuticals, Inc.
• View more press releases Close

Redes sociais sobre Arrowhead Pharmaceuticals

• Arrowhead Pharmaceuticals na Wikipedia, Google News e Yahoo Finance
• Arrowhead Pharmaceuticals na LinkedIn, Twitter e YouTube